About: Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 March 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) wüsseschaftlicher Artikel, wo im März 2000 veröffentlicht worden isch (gsw) im März 2000 veröffentlichter wissenschaftlicher Artikel (de) наукова стаття, опублікована в березні 2000 (uk) article scientifique publié en 2000 (fr) artículu científicu espublizáu en marzu de 2000 (ast) scientific article published on 01 March 2000 (en)
publication date	wds:Q73505522-4B2EA9B4-2055-49DB-BEB0-CA1BDF621AA4
publication date	2000-03-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73505522-C4FFE13E-F14E-4934-9CF3-1B9F9BE3A8DD
language of work or name	English
author name string	wds:Q73505522-E7E244DB-84F9-4117-95D6-4F3652C14FAF
author name string	Abciximab in Ischemic Stroke Investigators
rdfs:label	Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study (en) Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study (nl)
skos:prefLabel	Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study (en) Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study (nl)
name	Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study (en) Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study (nl)
title	wds:Q73505522-05950543-0B31-48A2-B4A4-ABA8DB1D2867
title	Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study (en)
page(s)	wds:Q73505522-7274EEF4-1FF1-4829-A693-2FBC38682F33
page(s)	601-609
instance of	wds:Q73505522-E5579153-6FB2-4E64-8782-F74F1BD15F10
instance of	scholarly article
main subject	wds:Q73505522-DC58C06F-A716-454E-8959-1264DA33D289
main subject	placebo
PubMed ID	wds:Q73505522-FB240CE8-682C-45FA-BF80-5D70020F7965
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10700492
PubMed ID	10700492
published in	wds:Q73505522-9E2B9CA2-6130-4AE4-953B-F8644470251D
published in	Stroke Journal
issue	wds:Q73505522-A23E16C6-71BA-4837-A325-D9D50CD61EC4
volume	wds:Q73505522-AE6AF12B-4229-43D4-A34A-93067AAF7877
issue	3
volume	31
DOI	wds:Q73505522-0E5C9548-16CF-469E-B4AB-1F1DD3013172
DOI	http://dx.doi.org/10.1161/01.STR.31.3.601
DOI	10.1161/01.STR.31.3.601
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73505522
is cites work of	Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding Antiplatelet therapy for acute ischaemic stroke Can the immune system be harnessed to repair the CNS? Tissue-type plasminogen activator as a therapeutic target in stroke Antiplatelet therapy for acute ischaemic stroke Endovascular approaches to acute stroke, part 1: Drugs, devices, and data Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. Oral antiplatelet therapy for acute ischaemic stroke Hemostasis and alterations of the central nervous system Predicting final extent of ischemic infarction using artificial neural network analysis of multi-parametric MRI in patients with stroke Thrombolytic treatment of acute cerebral infarction Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke Fibrinolysis and Beyond: Bridging the Gap between Local and Systemic Clot Removal Vertebrobasilar thrombolysis with intravenous tirofiban: case report Stroke: epidemiology, classification, risk factors, complications, diagnosis, prevention, and medical and dental management Future trials of endovascular mechanical recanalisation therapy in acute ischemic stroke patients - a position paper endorsed by ESMINT and ESNR : part II: methodology of future trials. Critical care of acute ischemic stroke Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke. A preliminary feasibility and safety study in a non-human primate model Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor Thrombolytic Therapy in Acute Ischemic Stroke. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke: scientific rationale and available evidence Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke Recanalization therapies in acute ischemic stroke: pharmacological agents, devices, and combinations Potential role of abciximab in ischemic cerebrovascular disease A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice. Established treatments for acute ischaemic stroke Treatments for stroke Plasminogen activators and ischemic stroke: conditions for acute delivery Prevention and treatment of thromboembolism during endovascular aneurysm therapy Acute ischaemic stroke treated with combined intra-arterial thrombolysis and intravenous tirofiban despite oral anticoagulant therapy at an international normalised ratio > or = 2.0. Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions. Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions. Glycoprotein IIb/IIIa inhibitors: current indications and future prospects Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease Severe intracranial hemorrhage after emergency carotid stenting and abciximab administration for postoperative thrombosis Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment Safety of abciximab administration during PCI of patients with previous stroke The endovascular management of intracranial vascular disease including the MERCI device Intra-Arterial Use of Abciximab in Thromboembolic Complications Associated with Cerebral Aneurysm Coiling: The London Ontario Experience. Antiplatelet therapy in secondary stroke prevention--state of the art Postoperative intracranial thrombolysis and angioplasty Abciximab for the treatment of acute distal embolization associated with internal carotid artery angioplasty Assessment of a patient with stroke neurological examination and clinical rating scales. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke Multi-bed vascular disease: past, present, and future The endovascular management of intracranial vascular disease including the MERCI device. Selection of anticoagulants or antiplatelet-aggregating agents for prevention of stroke Place of drug therapy in the treatment of carotid stenosis
is cites work of	wds:Q33417215-5981B88F-67A0-4309-AECA-07FF1EE2AAB9 wds:Q33842161-881408B8-4519-47FA-8CAD-2D32C193BA54 wds:Q33996788-5E059B3A-862D-4802-826C-17FD5DADA86D wds:Q36254835-7F1C769D-51D1-4610-9FC2-B5FB2FD23310 wds:Q37168160-870A334C-3B74-4D72-B7B9-CD043A18405F wds:Q34603396-03CB1BD5-132A-4BAF-AC93-D895A831B6EA wds:Q45242548-7D8E56FE-7FD3-40B2-AD3C-3C500DAAA882 wds:Q48294695-FBB4C33E-DD2A-4FFE-8126-43A571DCC529

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software